Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00295750 · ClinicalTrials.gov registry record · Phase 3
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 620
- Enrollment target
NCT00295750: Completed Phase 3 study, sponsored by Ferring Pharmaceuticals.
NCT00295750 is a Phase 3 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 620 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00295750, a Phase 3 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 620 participants
- Enrollment target
Study Summary
The study was a three-arm, active-control, multi-centre, parallel group study.
Primary Outcome
Kaplan-Maier estimates of the cumulative probabilities of testosterone \<=0.5 ng/mL from Day 28 to Day 364. The degarelix response rate estimation determined whether the lower bound of the 95% confidence interval for the cumulative probability of testosterone \<=0.5 ng/mL from Day 28 to Day 364 was no lower than 90%.
Interventions
- DRUG Degarelix
- DRUG Leuprolide 7.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 620 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
What the finished NCT00295750 record still lists
NCT00295750 is an interventional study that assigns participants to a tested intervention. The registered 620 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 2 interventions - of which Degarelix is the first listed.
NCT00295750 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00295750 about?
NCT00295750 is a clinical study titled "The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer". The study was a three-arm, active-control, multi-centre, parallel group study.
What is the current status of trial NCT00295750?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 620 participants. The study started on 2006-02. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00295750?
The interventions under investigation include: Degarelix (DRUG), Leuprolide 7.5 mg (DRUG).
Who is sponsoring clinical trial NCT00295750?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00295750's enrollment target sits among peer trials
620 589th of 2000 higher than 1,410 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02282969 · 620 participants
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
- NCT02838836 · 620 participants
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
- NCT05538910 · 620 participants · NA
Defining Neurobiological Links Between Substance Use and Mental Illness
- NCT05822466 · 620 participants · NA
Virtual Tai ji Quan Exercise to Prevent Falls in Older Adults
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia